- Home
- AUUD vs XBIO Comparison
AUUD vs XBIO Comparison
Compare AUUD & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- XBIO
- Stock Information
- Founded
- AUUD 2012
- XBIO N/A
- Country
- AUUD United States
- XBIO United States
- Employees
- AUUD N/A
- XBIO N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- XBIO Health Care
- Exchange
- AUUD Nasdaq
- XBIO Nasdaq
- Market Cap
- AUUD 4.2M
- XBIO 4.4M
- IPO Year
- AUUD 2021
- XBIO N/A
- Fundamental
- Price
- AUUD $2.05
- XBIO $3.39
- Analyst Decision
- AUUD
- XBIO Hold
- Analyst Count
- AUUD 0
- XBIO 1
- Target Price
- AUUD N/A
- XBIO N/A
- AVG Volume (30 Days)
- AUUD 2.9M
- XBIO 15.4K
- Earning Date
- AUUD 11-06-2025
- XBIO 11-11-2025
- Dividend Yield
- AUUD N/A
- XBIO N/A
- EPS Growth
- AUUD N/A
- XBIO N/A
- EPS
- AUUD N/A
- XBIO N/A
- Revenue
- AUUD N/A
- XBIO $2,446,221.00
- Revenue This Year
- AUUD N/A
- XBIO $1.99
- Revenue Next Year
- AUUD N/A
- XBIO $20.00
- P/E Ratio
- AUUD N/A
- XBIO N/A
- Revenue Growth
- AUUD N/A
- XBIO N/A
- 52 Week Low
- AUUD $1.85
- XBIO $2.20
- 52 Week High
- AUUD $14.60
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- AUUD 38.35
- XBIO 58.26
- Support Level
- AUUD $2.00
- XBIO $3.04
- Resistance Level
- AUUD $2.11
- XBIO $3.70
- Average True Range (ATR)
- AUUD 0.13
- XBIO 0.23
- MACD
- AUUD 0.06
- XBIO 0.05
- Stochastic Oscillator
- AUUD 40.00
- XBIO 65.93
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.